Etan R. Aber, MD, PhD, is a board-certified medical oncologist and physician-scientist with specialized expertise in precision oncology, clinical investigation, and developmental therapeutics. His clinical focus includes drug development and early phase clinical trials with a focus on solid tumors.
Dr. Aber completed comprehensive medical and scientific training through an MD/PhD program at Columbia University, followed by residency in Internal Medicine and advanced subspecialty training in Medical Oncology at the National Institutes of Health. His academic background also includes a summa cum laude degree from the University of Pennsylvania, where he studied the biological basis of behavior and conducted foundational research in cell biology and neuroscience.
Throughout his career, Dr. Aber has contributed to research that advances understanding of tumor biology, metastasis, and biomarker development. His work has spanned laboratory discovery and clinical investigation, including participation in multiple clinical trials aimed at developing more targeted and effective cancer therapies. He has co-authored publications in leading scientific journals and has been recognized with awards for research excellence.
Dr. Aber is committed to delivering personalized, evidence-based cancer care and to integrating emerging scientific insights into clinical practice. His ongoing professional interests include precision medicine, translational oncology, and improving outcomes for patients with both early and advanced cancers.
